title: Assessment of the safety of hydrogenated resistant maltodextrin: reverse mutation assay, acute and 90-day subchronic repeated oral toxicity in rats, and acute no-effect level for diarrhea in humans.
abstract: A series of safety assessments were performed on hydrogenated resistant maltodextrin prepared by converting the reducing terminal glucose of resistant maltodextrin into sorbitol. The reverse mutation assay did not show mutagenicity. Acute and 90-day subchronic oral toxicity studies in rats showed no death was observed in any groups, including the group receiving the highest single dose of 10 g/kg body weight or the highest dose of 5 g/kg body weight per day for 90 days. Mucous or watery stools were observed in the hydrogenated resistant maltodextrin treatment group on the acute study, which were transient and were associated with the osmotic pressure caused by intake of the high concentrations. Subchronic study showed dose-dependent increases in the weights of cecum alone, cecal contents alone, and cecum with cecal contents as well as hypertrophy of the cecal mucosal epithelium, which are considered to be common physiological responses after intake of indigestible carbohydrates. These results indicated that the no observed adverse effect level (NOAEL) of hydrogenated resistant maltodextrin was 10 g/kg body weight or more on the acute oral toxicity study and 5.0 g/kg body weight/day or more on the 90-day subchronic repeated oral toxicity study in rats. Further study performed in healthy adult humans showed that the acute no-effect level of hydrogenated resistant maltodextrin for diarrhea was 0.8 g/kg body weight for men and more than 1.0 g/kg body weight for women. The results of the current safety assessment studies suggest that hydrogenated resistant maltodextrin is safe for human consumption.
authors.affiliation: Research Laboratory, Matsutani Chemical Industry Co., Ltd., Itami City, Japan. yuko-yoshikawa@matsutani.co.jp
authors.forename: Yuko
authors.initials: Y
authors.lastname: Yoshikawa
authors.forename: Yuka
authors.initials: Y
authors.lastname: Kishimoto
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Tagami
authors.forename: Sumiko
authors.initials: S
authors.lastname: Kanahori
mesh_terms: D060433:Administration, Ophthalmic; D000328:Adult; D000818:Animals; D002432:Cecum / Q000187:drug effects; D003967:Diarrhea / Q000139:chemically induced*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005766:Gastrointestinal Contents / Q000187:drug effects; D006801:Humans; D006865:Hydrogenation; D006984:Hypertrophy; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009152:Mutagenicity Tests / Q000379:methods*; D019055:No-Observed-Adverse-Effect Level; D009997:Osmotic Pressure / Q000187:drug effects; D011134:Polysaccharides / Q000008:administration & dosage* / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D055815:Young Adult
chemical_list: D011134:Polysaccharides; C008315:maltodextrin